View Older Stories View More Recent Stories

May 8, 2023 01:09PM Form 13F-NT Atlas Venture Fund VIII, For: Mar 31
May 8, 2023 01:08PM Form 13F-HR Atlas Venture Associates For: Mar 31
May 8, 2023 01:07PM Form 13F-HR Atlas Venture Advisors, For: Mar 31
May 2, 2023 04:30PM Be Biopharma Announces First Scientific Disclosures and New Preclinical Data Supporting the Advancement of B Cell Medicines at the American Society of Gene & Cell Therapy 26th Annual Meeting
Apr 25, 2023 07:00AM Rectify Pharmaceuticals Appoints Sachiyo Minegishi as Chief Operating Officer
Apr 4, 2023 07:00AM Arkuda Therapeutics Strengthens Management Team to Support Ongoing Discovery and Translation to the Clinic
Mar 31, 2023 07:00AM Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update
Mar 23, 2023 04:32PM Clarivate (CLVT) Appoints Robert McNamara to its Board, Nominates Saurabh Saha to Board
Mar 23, 2023 04:30PM Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director
Mar 1, 2023 06:00AM Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology and Expand Pipeline of Durable Precision Genomic Medicines
Feb 28, 2023 07:00AM Third Annual Science2Startup (S2S)™ Symposium on May 3, 2023 Will Foster Collaboration Between Researchers, Entrepreneurs and Top Investors
Feb 14, 2023 04:44PM Form 13F-HR Atlas Venture Life Scien For: Dec 31
Feb 14, 2023 04:39PM Form SC 13D/A Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Feb 14, 2023 04:36PM Form SC 13G/A Akero Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Feb 14, 2023 04:32PM Form SC 13G/A Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Feb 14, 2023 04:32PM Form SC 13G/A Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Feb 14, 2023 04:27PM Form SC 13G/A Day One Biopharmaceutica Filed by: Atlas Venture Fund XI, L.P.
Feb 14, 2023 07:00AM Rectify Pharmaceuticals Expands Clinical Drug Development Expertise with Board and SAB Appointments
Jan 31, 2023 09:19AM Form 13F-NT Atlas Venture Associates For: Dec 31
Jan 31, 2023 09:16AM Form 13F-HR Atlas Venture Associates For: Dec 31
Jan 31, 2023 09:07AM Form 13F-NT Atlas Venture Associates For: Dec 31
Jan 31, 2023 09:03AM Form 13F-HR Atlas Venture Advisors, For: Dec 31
Jan 31, 2023 08:59AM Form SC 13G/A INTEGRAL AD SCIENCE HOLD Filed by: Atlas Venture Fund VIII, L.P.
Jan 31, 2023 08:57AM Form SC 13G/A Surface Oncology, Inc. Filed by: Atlas Venture Fund IX, L.P.
Jan 31, 2023 08:56AM Form 13F-NT Atlas Venture Fund VIII, For: Dec 31
Jan 17, 2023 12:24PM Forsee Power Announces the Appointment of Jean-Yves Quentel as Group CFO
Jan 13, 2023 04:51PM Form 4 Kymera Therapeutics, For: Jan 11 Filed by: Atlas Venture Associates Opportunity I, L.P.
Jan 12, 2023 10:00AM Versanis Announces Initiation of the BELIEVE Global Phase 2b Study of Bimagrumab as a Novel Treatment for Obesity
Jan 6, 2023 01:03PM Biotech Industry Leaders Join Deep Genomics Board of Directors and Scientific Advisory Board
Jan 3, 2023 09:29PM Form 4 Disc Medicine, Inc. For: Dec 29 Filed by: Atlas Venture Fund X, L.P.
Jan 3, 2023 09:22PM Form 3 Disc Medicine, Inc. For: Dec 29 Filed by: Atlas Venture Opportunity Fund II, L.P.
Dec 29, 2022 05:15PM Disc Medicine Announces Completion of Merger with Gemini Therapeutics
Dec 19, 2022 08:30AM CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development
Dec 16, 2022 05:04PM Form 4 Kymera Therapeutics, For: Dec 14 Filed by: Atlas Venture Associates Opportunity I, L.P.
Dec 15, 2022 04:06PM Form SC 13D/A Aerovate Therapeutics, Filed by: Atlas Venture Fund XII, L.P.
Dec 14, 2022 04:55PM Form 4 Dyne Therapeutics, Inc. For: Dec 12 Filed by: Atlas Venture Opportunity Fund II, L.P.
Dec 14, 2022 04:54PM Form 4 Day One Biopharmaceutica For: Dec 12 Filed by: Atlas Venture Fund XI, L.P.
Dec 12, 2022 07:00AM Rectify Pharmaceutical Announces Publication of Trends in Molecular Medicine Review Article Highlighting the Therapeutic Potential of the ABC Transporter Superfamily
Dec 8, 2022 06:30AM Be Biopharma Appoints John Mayfield, Ph.D., as Chief Business Officer
Dec 6, 2022 05:01PM Form SC 13D/A Replimune Group, Inc. Filed by: Atlas Venture Fund X, L.P.
Nov 10, 2022 06:56AM Form 13F-HR Atlas Venture Associates For: Sep 30
Nov 10, 2022 06:55AM Form 13F-HR Atlas Venture Advisors, For: Sep 30
Nov 10, 2022 06:53AM Form 13F-NT Atlas Venture Associates For: Sep 30
Nov 10, 2022 06:53AM Form 13F-NT Atlas Venture Fund VIII, For: Sep 30
Nov 10, 2022 06:53AM Form 13F-NT Atlas Venture Associates For: Sep 30
Nov 9, 2022 04:28PM Form 13F-HR Atlas Venture Life Scien For: Sep 30
Nov 4, 2022 04:32PM Form 4 Kymera Therapeutics, For: Nov 02 Filed by: Atlas Venture Associates Opportunity I, L.P.
Nov 3, 2022 04:15PM Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results
Nov 3, 2022 04:15PM Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results
Nov 2, 2022 07:00AM Versanis Presents Preclinical Data Demonstrating the Potential of Bimagrumab as a Novel Obesity Treatment at ObesityWeek 2022
View More Recent Stories View Older Stories